<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886714</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL18_0015</org_study_id>
    <secondary_id>UF 7561</secondary_id>
    <nct_id>NCT03886714</nct_id>
  </id_info>
  <brief_title>Screening for Fabry Disease in Renal Transplantation</brief_title>
  <acronym>DEFYT</acronym>
  <official_title>Screening for Fabry Disease in Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single centre, prospective pilot study examining the relevance to screen for Fabry disease in
      a cohort of patients who have undergone renal transplantation for nephropathy of
      indeterminate cause, vascular nephropathy, diabetic nephropathy or secondary focal segmental
      hyalinosis with no established cause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploration whether Fabry disease cases can be identified among patients who are followed at
      the Montpellier University Hospital after renal transplantation, with indeterminate cause of
      renal failure or diabetic nephropathy (due to its high frequency) or secondary focal
      segmental hyalinosis (FSH).

      At the population level, the identification of cases at the Montpellier centre could then
      justify to expand this screening to other French centres. The goal is to contribute to adapt
      current guidelines of renal failure assessment, by systematically including Fabry among the
      diagnostic tests. Whether all patients with renal failure are concerned, or only those with
      indeterminate cause, is an important question this study will address.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2019</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients with Positive screen result</measure>
    <time_frame>Inclusion visit</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">676</enrollment>
  <condition>Fabry Disease</condition>
  <condition>Nephropathy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Screening for Fabry disease</intervention_name>
    <description>Screening for the α-galactosidase (GAL) enzyme activity (men + women) and plasma Lyso globotriaosylsphingosine (GL3, women) for the diagnosis of Fabry disease.</description>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Screen for α-galactosidase mutation</intervention_name>
    <description>If necessary (positive for GAL), genetic confirmation tests for Fabry disease will be performed (men + women).</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two 9 mL EDTA (ethylenediaminetetraacetic acid) blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients identified from a database, who have undergone renal transplantation for
        nephropathy of indeterminate cause, vascular nephropathy, diabetic nephropathy or secondary
        focal segmental hyalinosis with no established cause, and still followed at the Montpellier
        University Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Nephropathy of indeterminate cause, or secondary FSH or diabetic nephropathy

          -  Patients with kidney transplanted

          -  Patients still followed at the Montpellier University Hospital

          -  Obtaining written informed consent

          -  Age &gt; 18 years old, no upper age limit

        Exclusion Criteria:

          -  N/A
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Moglie Le Quintrec, Pr</last_name>
    <phone>0467338456</phone>
    <email>m-lequintrec-donnette@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MOGLIE LE QUINTREC DONNETTE, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fabry disease</keyword>
  <keyword>Renal transplantation</keyword>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Focal Segmental Hyalinosis (FSH)</keyword>
  <keyword>Undetermined nephropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

